CTNI-40. EVALUATING FEASIBILITY AND EFFICIENCY OF PHASE II ADAPTIVE PLATFORM TRIAL DESIGNS BASED ON THE INDIVIDUALIZED SCREENING TRIAL OF INNOVATIVE GLIOBLASTOMA THERAPY (INSIGhT) EXPERIENCE. (12th November 2021)

• Record Type: Journal Article
• Authors: Rahman, Rifaquat; Trippa, Lorenzo; Lee, Eudocia Quant; Arrillaga-Romany, Isabel; Touat, Mehdi; Fell, Geffrey; McCluskey, Christine; Bruno, Jennifer; Gaffey, Sarah; Drappatz, Jan; Lassman, Andrew; Galanis, Evanthia; Ahluwalia, Manmeet; Colman, Howard; Nabors, L Burt; Hepel, Jaroslaw; Elinzano, Heinrich; Schiff, David; Chukwueke, Ugonma; Beroukhim, Rameen; Batchelor, Tracy; Nayak, Lakshmi; McFaline-Figueroa, J Ricardo; Rinne, Mikael; Kaley, Thomas; Lu-Emerson, Christine; Bi, Wenya Linda; Arnaout, Omar; Haas-Kogan, Daphne; Tanguturi, Shyam; Cagney, Daniel; Aizer, Ayal; Welch, Mary; Doherty, Lisa; Lavallee, Maria; Fisher-Longden, Brittany; Dowling, Shanna; Pisano, William; Lapinskas, Emily; Meredith, David; Chiocca, E Antonio; Reardon, David; Ligon, Keith; Alexander, Brian; Wen, Patrick;
• Is Part Of: Neuro-oncology. Volume 23: Supplement 6(2021)
• Page Start: vi68
• Page End: vi69
• Publication Date: 2021-11-12
• Subjects: Brain Neoplasms -- Periodicals; Brain -- Tumors -- Periodicals; Brain -- Cancer -- Periodicals; Nervous system -- Cancer -- Periodicals; 616.99481
• DOI: 10.1093/neuonc/noab196.265
• Languages: English
• ISSNs: 1522-8517

Abstract

Abstract: BACKGROUND: The Individualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT) is a phase II platform trial with Bayesian adaptive randomization and deep genomic profiling to more efficiently test experimental agents in newly diagnosed glioblastoma and to prioritize therapies for late-stage testing. METHODS: In the ongoing INSIGhT trial, patients with newly diagnosed MGMT-unmethylated glioblastoma are randomized to the control arm or one of three experimental therapy arms (CC-115, abemaciclib, and neratinib). The control arm therapy is radiotherapy with concomitant and adjuvant temozolomide, and primary endpoint is overall survival. Randomization has been adapted based on Bayesian estimation of biomarker-specific probability of treatment impact on progression-free survival (PFS). All tumors undergo detailed molecular sequencing, and this is facilitated with the companion ALLELE protocol. To evaluate feasibility of this approach, we assessed the status of this ongoing trial. RESULTS: Since INSIGhT was activated 4.3 years ago, it has expanded to include 12 sites across the United States. A total of 247 patients have been enrolled. Randomization probabilities have been repeatedly adjusted over time based upon early PFS results to alter the randomization ratio from standard 1:1:1:1 randomization. All three arms have completed accrual and efficacy estimates are available based upon comparison to the common control arm in context of relevant biomarkers. There are 87 patients alive and in follow-up, and there are ongoing plans to add additional arms to evaluate further treatments in the future. CONCLUSION: The INSIGhT trial demonstrates that a multi-center Bayesian adaptive platform trial is a feasible and effective approach to help prioritize therapies and biomarkers for newly diagnosed GBM. The trial has maintained robust accrual, and the simultaneous testing of multiple agents, sharing a common control arm and adaptive randomization serve as features to increase trial efficiency relative to traditional clinical trial designs.